Ligand Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 100   

Articles published

LGND 53.97 -0.16 (-0.30%)
price chart
Will Ligand Pharmaceuticals Beat Q3 Earnings Estimates?
Ligand Pharmaceuticals Incorporated (LGND - Snapshot Report) is scheduled to report third-quarter 2014 results before the opening bell on Oct 27.
Will Agenus (AGEN) Incur Wider-than-Expected Q3 Loss? - Analyst Blog  DigitalJournal.com (blog)
Related articles »  
Why Lemelson Capital Is Short On Ligand Pharmaceuticals
Rev. Emmanuel Lemelson is the chief investment officer of Lemelson Capital Management, an investment firm that is short in Ligand Pharmaceuticals Inc. (NASDAQ: LGND). Lemelson recently joined Benzinga's #PreMarket Prep to talk about why he thinks ...
Ligand Pharmaceuticals Director Purchases $91360 in Stock (LGND)  sleekmoney
Related articles »  
Ligand Pharmaceuticals PT Raised to $121.50 at Roth Capital (LGND)
Ligand Pharmaceuticals Inc. logo Research analysts at Roth Capital boosted their price target on shares of Ligand Pharmaceuticals (NASDAQ:LGND) from $92.00 to $121.50 in a report released on Thursday.
Ligand Pharmaceuticals Price Target Raised to $121.50 at Roth Capital (LGND)  Mideast Time
Related articles »  
Ligand Pharmaceuticals Inc. (LGND), Inovio Pharmaceuticals Inc (INO), & Tejon ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and Inovio Pharmaceuticals Inc (NASDAQ:INO) are two stocks from the pharma space that have recently seen insiders buying shares in large quantities.
Ligand Pharmaceuticals Inc. (LGND) Insider Dumps 11000 Shares  Tech Insider
Ligand Pharmaceuticals Inc. (LGND) Releases FY14 Earnings Guidance  Watch List News (press release)
Related articles »  
Ligand Pharmaceuticals Inc. Shares Gain On Q3 Pre-Announcement
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) ticked up Wednesday after the company said third-quarter results will be better than expected.
Ligand Pharmaceuticals Inc. (LGND) Issues FY14 Earnings Guidance  sleekmoney
Related articles »  
Ligand Pharmaceuticals Inc. (LGND) Insider Raises Profile By Over 20000 Shares
Ligand Pharmaceuticals Inc.(NASDAQ:LGND) saw an insider lower his exposure to the company today. The Director Jason Aryeh acquired 20,300 shares of common stock at prices ranging from $6.82 to $17.88 per share.
Ligand Pharmaceuticals Receives "Hold" Rating from Cantor ...  sleekmoney
Insider Trade Report For Ligand Pharmaceuticals  Markets Insider
Related articles »  
Cantor Fitzgerald Reaffirms "Hold" Rating for Ligand Pharmaceuticals (LGND)
Ligand Pharmaceuticals Inc. logo Ligand Pharmaceuticals (NASDAQ:LGND)'s stock had its �hold� rating reiterated by Cantor Fitzgerald in a research note issued on Thursday.
Ligand Earns Milestone Payment Triggered by EU Approval of Merck's ...  MarketWatch
Related articles »  
Ligand Pharmaceuticals Upgraded by Zacks to "Outperform" (LGND)
Ligand Pharmaceuticals Inc. logo Ligand Pharmaceuticals (NASDAQ:LGND) was upgraded by Zacks from a �neutral� rating to an �outperform� rating in a report released on Tuesday.
Insiders Now Seeing Red With LGND At New 52-Week Low  NASDAQ
Related articles »  
Ligand Pharmaceuticals Receives Average Recommendation of "Hold" from ...
Ligand Pharmaceuticals (NASDAQ:LGND) traded down 2.48% during mid-day trading on Monday, hitting $49.53. 379,317 shares of the company's stock traded hands. Ligand Pharmaceuticals has a 1-year low of $39.75 and a 1-year high of $80.42.
Related articles »  
Insider Trading Alert : MICRON TECH , ARROWHEAD RESEARCH , LIGAND ...
LIGAND PHARMACEUTICALS INC (LGND) Executive KOZARICH JOHN W initiated a Buy transaction dated Wednesday 15 October 2014 for 2,000 shares.
Related articles »